PMID- 26174902
OWN - NLM
STAT- MEDLINE
DCOM- 20150928
LR  - 20150716
IS  - 1537-2995 (Electronic)
IS  - 0041-1132 (Linking)
VI  - 55 Suppl 2
DP  - 2015 Jul
TI  - Specifications for anti-A and anti-B in intravenous immunoglobulin: history and 
      rationale.
PG  - S80-5
LID - 10.1111/trf.13091 [doi]
AB  - Intravenous immunoglobulin (IVIG) products are generally safe and efficacious, 
      although treatment-related adverse reactions can occur in recipients. Adverse 
      reactions include hemolysis in non-blood group O recipients linked to the passive 
      transfer of anti-A and/or anti-B present in the fractionated immunoglobulin 
      product. In light of the recent increase in reported cases of severe hemolysis 
      associated with anti-A and/or anti-B, this article traces the development of 
      pharmacopoeial specifications, tests, and reference reagents to control their 
      titers in IVIG products.
CI  - (c) 2015 AABB.
FAU - Thorpe, Susan J
AU  - Thorpe SJ
AD  - Biotherapeutics Group, National Institute for Biological Standards and Control, 
      Medicines and Healthcare Products Regulatory Agency, Herts, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (ABO Blood-Group System)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Isoantibodies)
SB  - IM
MH  - ABO Blood-Group System/*immunology
MH  - *Hemolysis/drug effects/immunology
MH  - Humans
MH  - Immunoglobulins, Intravenous/*adverse effects/*immunology/therapeutic use
MH  - Isoantibodies/*adverse effects/*immunology
EDAT- 2015/07/16 06:00
MHDA- 2015/09/29 06:00
CRDT- 2015/07/16 06:00
PHST- 2015/07/16 06:00 [entrez]
PHST- 2015/07/16 06:00 [pubmed]
PHST- 2015/09/29 06:00 [medline]
AID - 10.1111/trf.13091 [doi]
PST - ppublish
SO  - Transfusion. 2015 Jul;55 Suppl 2:S80-5. doi: 10.1111/trf.13091.